Therapeutic efficacy of infused molecular hydrogen in saline on rheumatoid arthritis: a randomized, double-blind, placebo-controlled pilot study.
Toru Ishibashi, Bunpei Sato, Shinji Shibata, Takaaki Sakai, Yuichi Hara, Yuji Naritomi, Samon Koyanagi, Hiroshi Hara, Tetsuhiko Nagao · International immunopharmacology · 2014
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In 1 patients, iL-6 levels in the H₂ group significantly decreased in 4 weeks by 37.3 ± 62.0% compared to baseline, whereas it increased by 33.6 ± 34.4% in the placebo group. These findings add human evidence supporting molecular hydrogen's therapeutic potential for rheumatoid arthritis.
What the Findings Mean
H2HUBB reviewed how molecular hydrogen affected the outcomes measured in 1 patients. IL-6 levels in the H₂ group significantly decreased in 4 weeks by 37.3 ± 62.0% compared to baseline, whereas it increased by 33.6 ± 34.4% in the placebo group.
What the Researchers Studied
The researchers studied 1 patients. The study used a randomized, double-blind, placebo-controlled human clinical trial. The comparison condition was placebo.
What Effects Did Molecular Hydrogen Have?
IL-6 levels in the H₂ group significantly decreased in 4 weeks by 37.3 ± 62.0% compared to baseline, whereas it increased by 33.6 ± 34.4% in the placebo group.
Why These Findings Matter
These findings add human evidence supporting molecular hydrogen's therapeutic potential for rheumatoid arthritis and contribute to the growing body of molecular-hydrogen research.
How Strong Is This Evidence?
This is human clinical evidence from a randomized, double-blind, placebo-controlled human clinical trial. H2HUBB interprets the findings in the context of the study design, sample, comparator, and measured outcomes rather than using one publication as a verdict on hydrogen therapy.
Technical Study Details
H2HUBB classifies this publication as human clinical study with human clinical evidence. The research population or model was 1 patients. The study used a randomized, double-blind, placebo-controlled human clinical trial.
Limitations and Safety
No separate limitations or safety findings were identified in the source text available to H2HUBB.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.